

Ending the Syndemic (SUD/HCV/HIV/STI) at Your Tribe or Facility

September 10, 2024

ECHO
LEADING THE WAY

Jorge Mera, MD, FACP | ECHO Medical Director | Northwest Portland Area Indian Health Board | jorge-mera@cherokee.org

Growing the Ability to Deliver Quality Healthcare to American Indian and Alaska Native People.

Learning Objectives, Participants will be able to:

Explain the concept of a Syndemic

Recognize the impact of the opioid epidemic in relation to the HIV and HCV epidemics

Describe interventions to mitigate the HIV/STI/SUD/HCV syndemic at a Macro, Micro and individual level





Syndemic concepts



Clinical case



The SUD | HCV | HIV | STI syndemic in Indian Country




Interventions to mitigate the syndemic




Conclusions

Syndemic Core Principles


- Clustering of two or more conditions in a specific population
- Their synergism in producing excess burden of disease in a population
- Precipitation and propagation by large scale behavioral, structural and social forces



HIV Syndemic Outcomes



Viral suppression rates by number of co-infections



- > Syndemics are associated with poorer HIV health outcomes among PLWHA
- Significant "dose-response relationship" between the number of co-infections and mean VLs
- In addition to numbers of co-infections, particular demographic subgroups, and certain geo-clusters were also associated with poorer health outcomes, underscoring the need to address multiple conditions in tandem in an I integrated health system

Indiana HIV/HCV/SUD Outbreak

Community in Scott County, Indiana From 2004-2013

- Population of ~ 4200
- Only 5 infections had been diagnosed from 2004-2013

In January 2015


- ISDH investigates a cluster of 11 newly diagnosed HIV infections
- Identified by an alert disease intervention specialist

From November 18, 2014 – November 1, 2015

- HIV infection was diagnosed in 181 case patients.
- 92.3% were coinfected with HCV
- Most patients (87.8%) reported injecting oxymorphone an extended-release semi-synthetic opioid analgesic

All cases were epidemiologically linked

Infections were recent and from a single HIV strain



N Engl J Med 2016;375:229-239

Indiana HIV/HCV Outbreak: Syndemic Risk Factors in Scott County

Social Factors

- High poverty (19.0%)
- Unemployment (8.9%)
- Few affected persons had medical insurance
- Low educational attainment (21.3% no high school)

Structural Factors

- Syringe service programs not permitted by state law
- Scarce HIV/HCV care available
- Limited substance use disorder services


Behavioral Factors

Sharing of paraphernalia

How Was the Outbreak Controlled?


One stop shop

- Behavioral health treatment
- HIV/MAT/HCV care provided
- SSP emergency authorization



N Engl J Med 2016;375:229-239

Syndemic



Maria Yellow Horse Brave Heart Journal of Psychoactive Drugs Vol. 35, Iss. 1, 2003





Syndemic concepts



Clinical case



The SUD | HCV | HIV | STI syndemic in Indian Country



Interventions to mitigate the syndemic



Conclusions

Clinical Case: Mrs. S

Mrs. S is a 20 yo cisgender female who has sex with cis-gender males, who presents for a pregnancy test only

- Reports having oral and vaginal sex without protective barrier
 3 weeks ago
- Reports sex with 2 partners over the **past 6 months**
- Denies recent drug use, but reports injecting heroin 3 months ago
- Reports unstable housing and transportation and does not have regular access to phone

No current signs or symptoms, and doesn't recollect any in the past year

- Never tested for HIV
- Last gonorrhea/chlamydia (urine only) and RPR tests were all negative 11 months ago

Clinical Case: Mrs. S

Office Tests

- Rapid pregnancy test: Positive
- Agrees to rapid HIV/Syphilis test in office when offered incentive
- HIV: non-reactive
- Syphilis (treponemal antibody):
 reactive

What are the recommended next steps? (Check all that apply)

- A. No further testing necessary, as initial reason for the visit (pregnancy testing) already completed
- B. Draw blood for HIV, obtain urine/anal/throat swab for G/C
- C. Draw blood for RPR, wait for results to determine treatment
- D. Draw RPR and immediately administer 2.4 MU IM injection of benzathine penicillin G (BPG) for early latent stage syphilis
- E. Draw RPR and immediately administer 2.4 MU IM injection of BPG weekly x 3 weeks (total 7.2 MU) for late latent stage syphilis

Outline



Syndemic concepts



Clinical case



The SUD | HCV | HIV | STI syndemic in Indian Country




Interventions to mitigate the syndemic



Conclusions


STI Overview

Chlamydia, gonorrhea, and syphilis cases have been increasing for years.



People most affected by STIs include:





→ Pregnant people

15-24 years

People from some racial and ethnic minority groups







STIs & Substance Use




Use of opioids and other substances has been linked to increasing STIs and outbreaks of infectious diseases.




Young adults who used an illicit drug* in the past year were 3 times more likely to get an STI.

U.S. Syphilis Cases in Newborns Continue to Increase: A 10-Times Increase Over a Decade



Congenital Syphilis — Rates of Reported Cases by Year of Birth, Race/Hispanic Ethnicity of Mother, United States, 2018–2022



^{*} Per 100,000 live births



Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis — United States, 2013–2017

Among women and MSW with P&S syphilis

 Reported use of methamphetamine, injection drugs, and heroin more than doubled during 2013–2017.

In 2017, women with P&S syphilis

- 16.6% used methamphetamine
- 10.5% used injection drugs
- 5.8% used heroin during the preceding 12 months.

HHS Announces Department Actions to Slow Surging Syphilis Epidemic

Primary, secondary and congenital syphilis rates are highest in AI/AN

- Comparable to rates from the pre-penicillin era
- For every 155 AI/AN births in 2022, there was one congenital syphilis case.

Most syphilis cases were diagnosed outside of STD clinics in 2022

 Emphasizing the role of HCW in primary care, emergency departments, community health, correctional and drug treatment programs

American Indian/Alaska Native (AI/AN) HCV Statistics in the United States

HCV disproportionately affects AI/AN^{1,2}

The incidence rate of acute hepatitis C among AI/AN has remained substantially higher than other racial/ethnic populations

• From 2003 to 2018. In 2018, the rate of incident acute hepatitis C was higher among Al/AN (3.6 per 100,000) than among non-Hispanic whites (1.3 per 100,000)³

Compared to the overall population, non-Hispanic AI/AN persons had a much higher age-adjusted hepatitis C-related death rate

- In 2021 (3.18 vs. 9.99 per 100,000, respectively)
- 1. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis: United States, 2016. Retrieved from https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm
- 2. Center for Disease Control and Prevention. Deaths: Final Data for 2014. http://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65 04.pdf
- 3. Office of Infectious Disease and HIV/AIDS Policy (OIDP)
 Content last reviewed June 5, 2024US Census Bureau. https://www.census.gov/www. Accessed Nov 2, 2019


Age-adjusted rate* of hepatitis C-related deaths† among non-Hispanic American Indian/Alaska Native persons‡ and annual targets for the United States by year



- * Rates are per 100,000 population and age-adjusted to the 2000 US Standard Population.
- [†] Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International Classification of Disease, 10th Revision (ICD-10) codes B17.1 or B18.2.²
- ‡ Excludes those reporting Hispanic or Latino origin.


- Compared to the overall population, non-Hispanic AI/AN persons had a much higher ageadjusted hepatitis C-related death rate in 2021 (3.18 vs. 9.99 per 100,000, respectively).
- Although the death rate decreased slightly from 10.24 per 100,000 in the 2017 baseline year, the rate of 9.99 in 2021 remains above the target rate of 8.19.
- The overall increase in US deaths due to the COVID-19 pandemic during 2020 and 2021 may have affected the hepatitis C-related death rates in these two years; therefore, 2020 and 2021 data should be interpreted with caution

Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014: A Study of Health Care Encounter Data



Overall national annual rates (per 10 000 adults) of diagnoses among American Indian/Alaska Native persons for hepatitis C virus (HCV) infection, opioid use disorder, arm cellulitis and abscess, and opioid-related overdose, Indian Health Service, 2010-2014. Rates of diagnoses represent 1 health care encounter per person per year. Data for HCV infections are for adults aged 18-35; all other data are for adults aged ≥18. Arm cellulitis was counted only among adults with no diabetes on or before the health care encounter for arm cellulitis visit (since 2001). Data source: National Patient Information Reporting System.

Trends in HIV diagnoses in the US and 6 territories and freely associated states by race and ethnicity, 2018-2022*



^{*}Among people aged 13 and older.


Source: CDC. Diagnoses, deaths, and prevalence of HV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2022;35.


⁺ Changes in subpopulations with fewer HIV diagnoses can lead to a large percentage increase or decrease.

^{*} Black refers to people having origins in any of the Black racial groups of Africa. African American is a term often used for people of African descent with ancestry in North America.

^{**} Hispanic/Latino people can be of any race.

HIV Diagnoses Among American Indian/Alaska Native People by Transmission Category and Sex at Birth[†], 2022 – United States





The terms male-to-male sexual contact (MSM) and male-to-male sexual contact and injection drug use (MSM/IDU) are used in CDC surveillance systems. They indicate the behaviors that transmit HIV infection, not how individuals self-identify in terms of their sexuality.

Disparities in HIV Experienced by American Indian/Alaska Native People in 2022

Between 2018 and 2022, new HIV diagnoses among AI/AN people increased by 30%

- -From 166 new HIV diagnoses in 2018 to 215 new HIV diagnoses in 2022.
- -The rate of new HIV diagnoses among AI/AN people was 10.6/per 100,000 (Twice the rate of experienced by Whites)



AI/AN people had the lowest level of knowledge of HIV status

-(77.3%) than any other racial or ethnic group.



The rate of diagnosis of HIV infection among AI/AN women (5.5%)

- -Is over twice as high as the rate of diagnosis among White women (1.9%).
- -Had the second highest percentage (46%) of HIV infections attributable to IDU compared to women in other racial or ethnic groups.

HIV, HCV, STIs, Drug Use Among AI/AN



AI/AN had the highest percent of estimated diagnoses of HIV infection attributed to injection drug use



Syphilis rates including congenital syphilis are rapidly increasing

Exacerbates HIV transmission



Drug use is increasing nationwide and in Indian Country



AI/AN have greatest rates of new HCV diagnoses

Over 2x national rate of HCV-related mortality

Rates are decreasing with greater availability of treatment





Syndemic concepts



Clinical case



The SUD | HCV | HIV | STI syndemic in Indian Country



Interventions to mitigate the syndemic



Conclusions

What can we do to mitigate the syndemic?







AS A PRIMARY CARE HEALTH WORKER?

(INDIVIDUAL)

AS HEALTH SYSTEM LEADERSHIP? (MICRO)

AS A SOCIETY (MACRO)

Actions to Address the Syndemic Among People Who Inject Drugs as a Primary Care Health Care Worker

Screening

Patients for SUDs and mental health disorders

Testing

Patients and their sexual or drug-injection partners for HIV, HCV, and STIs

Offering immediate treatment according to established guidelines

Actions to Address the Syndemics Among People Who Inject Drugs as a Primary Care Health Care Worker



Providing

Hep B vaccinations
Naloxone to opioid users and their families/partners

Acquiring

Training to provide opioid agonist therapy


Supporting

People who inject drugs by providing sterile syringes or referring them to syringe service programs

What can the Healthcare Worker do for Mrs. S?



What can the Health Care system (Leadership) do for to Mitigate the Syndemic (Micro level)



What Can Society Do To Mitigate the Syndemic (Macro level)?

- Decrease Injection Drug Use a make it safer
 - Make SSP available
 - Easy access to MAT
 - Easy access to behavioral health
- Eliminate social and structural determinants of injection drug use
 - Poverty (Decrease the economic inequality gap)
 - Housing
 - Lack of education
 - Racism
 - Stigma
 - Mass incarceration (Reform drug laws)

Addressing the root of the problem is critical for the elimination of present SUD/HCV/HIV/STI syndemic and the prevention of future ones

A coordinated approach between society, government, public health will be needed

"No-Wrong Door Approach"

Holistic, Coordinated Care Is Critical for Addressing These Overlapping Epidemics



A "no-wrong-door" approach – providing or connecting a person to all the services that meet their needs wherever they seek care – is crucial.

The first step in implementing this approach is **increasing access to quality healthcare settings.** STD clinics are important spaces for people who are uninsured, need flexible appointments, need low- or no-cost services, or are looking for expert and confidential services.

We must reduce the effect of social and economic conditions that can influence health outcomes - called social determinants of health - which have been documented as key contributors to negative health outcomes, including STI transmission. Strategies to reduce these conditions can include:

- **▼** Promoting prevention and care in related systems, including housing, education, and the justice system.
- Providing patients with resources, including housing, food, transportation, and employment.
- Integrating existing programs, such as syringe services, substance use disorder treatment programs, and HIV testing and pre-exposure prophylaxis programs in STD clinics.
- Identifying "outside-the-box" opportunities for collaboration and integration. New solutions could include developing partnerships with pharmacies and retail health clinics or modernizing and streamlining data systems.

Clinical Case: Mrs. S

Mrs. S is a 20 yo cis-gender female who has sex with cis-gender males, who presents for a pregnancy test only

- Reports having oral and vaginal sex without protective barrier 3 wks ago
- Reports sex with 2 partners over the past 6 months
- Denies recent drug use, but reports injecting heroin 3 months ago
- Reports unstable housing and transportation and does not have regular access to phone

No current signs or symptoms, and doesn't recollect any in the past year

- Never tested for HIV
- Last gonorrhea/chlamydia (urine only) and RPR tests were all negative 11 months ago

Office Tests

- Rapid pregnancy test: Positive
- Agrees to rapid HIV/Syphilis test in office when offered incentive
- HIV: non-reactive
- Syphilis (treponemal antibody): reactive


What are the recommended next steps? (Check all that apply)

- A. No further testing necessary, as initial reason for the visit (pregnancy testing) already completed
- B. Draw blood for HIV, obtain urine/anal/throat swab for G/C
- C. Draw blood for RPR, wait for results to determine treatment
- D. Draw RPR and immediately administer 2.4 MU IM injection of benzathine penicillin G (BPG) for early latent stage syphilis
- E. Draw RPR and immediately administer 2.4 MU IM injection of BPG weekly x 3 weeks (total 7.2 MU) for late latent stage syphilis

What are the recommended next steps? (Check all that apply)

- A. No further testing necessary, as initial reason for the visit (pregnancy testing) already completed
- B. Draw blood for HIV, obtain urine/anal/throat swab for G/C
- C. Draw blood for RPR, wait for results to determine treatment
- D. Draw RPR and immediately administer 2.4 MU IM injection of benzathine penicillin G (BPG) for early latent stage syphilis
- E. Draw RPR and immediately administer 2.4 MU IM injection of BPG weekly x 3 weeks (total 7.2 MU) for late latent stage syphilis

What else would you recommend for Mrs. S?



Conclusions

Ending the syndemic will require a multipronged approach

SUD services should be integrated into primary care – barriers for harm reduction should be removed

The efficacy of PrEP and HIV treatment has been established – access for the most vulnerable is critical

Syphilis is taking a toll in AI/AN communities – zero tolerance for congenital syphilis should be the standard

References

- Singer, M. and Clair, S. (2003), Syndemics and Public Health: Reconceptualizing Disease in Bio-Social Context. Medical Anthropology Quarterly, 17: 423-441. https://doi.org/10.1525/maq.2003.17.4.423
- Chu PL, Santos GM, Vu A et al. Journal of the International AIDS Society 2012. 15:102-103
- Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone Indiana, 2015 MMWR May 1, 2015 / 64(16):443-444
- US Census Bureau. https://www.census.gov/www. Accessed March 22, 2021
- Evans ME, Person M, Reilley B, et al. Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014: A Study of Health Care Encounter Data. Public Health Rep. 2020 Jul/Aug;135(4):461-471. doi: 10.1177/0033354920937284. Epub 2020 Jul 7. PMID: 32633599; PMCID: PMC7383762.
- Viral Hepatitis Surveillance Report 2018 Hepatitis C https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepC.htm
- Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010-2015. *Cancer Epidemiol Biomarkers Prev.* 2019;28(10):1604-1611. doi:10.1158/1055-9965.EPI-19-0288
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention. https://www.cdc.gov/hiv/group/racialethnic/aian/index.html

References

- Sordo L, Barrio G, Bravo M J, Indave B I, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies BMJ 2017; 357:j1550 doi:10.1136/bmj.j1550
- Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. *JAMA Netw Open*. 2019;2(6):e196373. doi:10.1001/jamanetworkopen.2019.6373
- Reilley B, Haberling DL, Person M, Leston J, Iralu J, Haverkate R, Siddiqi AE. Assessing New Diagnoses of HIV Among American Indian/Alaska Natives Served by the Indian Health Service, 2005-2014. Public Health Rep. 2018 Mar/Apr;133(2):163-168. doi: 10.1177/0033354917753118. Epub 2018 Mar 8. PMID: 29517957; PMCID: PMC5871137.
- Lauren Canary, Susan Hariri, Cecily Campbell, et al., Geographic Disparities in Access to Syringe Services Programs Among Young Persons With Hepatitis C Virus Infection in the United States, *Clinical Infectious Diseases*, Volume 65, Issue 3, 1 August 2017, Pages 514–517
- Paquette CE, Pollini RA. Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review. Drug Alcohol Depend. 2018 Jul 1;188:239-250. doi: 10.1016/j.drugalcdep.2018.03.049. Epub 2018 May 8. PMID: 29787966; PMCID: PMC5999584.
- Jon E. Zibbell, Alice K. Asher, Rajiv C. Patel, et al. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. J Public Health. 2018 Feb; 108(2): 175–181.

